A detailed history of Resources Management Corp transactions in Eli Lilly & CO stock. As of the latest transaction made, Resources Management Corp holds 1,710 shares of LLY stock, worth $1.36 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
1,710
Previous 1,467 16.56%
Holding current value
$1.36 Million
Previous $1.33 Million 14.08%
% of portfolio
0.2%
Previous 0.19%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$772.14 - $960.02 $187,630 - $233,284
243 Added 16.56%
1,710 $1.52 Million
Q2 2024

Aug 14, 2024

SELL
$724.87 - $909.04 $5,798 - $7,272
-8 Reduced 0.54%
1,467 $1.33 Million
Q1 2024

May 15, 2024

BUY
$592.2 - $792.28 $49,744 - $66,551
84 Added 6.04%
1,475 $1.15 Million
Q4 2023

Feb 14, 2024

BUY
$525.19 - $619.13 $424,353 - $500,257
808 Added 138.59%
1,391 $811,000
Q4 2023

Feb 14, 2024

SELL
$525.19 - $619.13 $395,468 - $466,204
-753 Reduced 56.36%
583 $811,000
Q3 2023

Nov 16, 2023

BUY
$434.7 - $599.3 $76,072 - $104,877
175 Added 15.07%
1,336 $717,000
Q2 2023

Aug 16, 2023

BUY
$350.74 - $468.98 $325,837 - $435,682
929 Added 400.43%
1,161 $544,000
Q1 2023

May 11, 2023

SELL
$310.63 - $364.82 $39,760 - $46,696
-128 Reduced 35.56%
232 $13,000
Q2 2022

Aug 10, 2022

BUY
$278.73 - $327.27 $2,787 - $3,272
10 Added 2.86%
360 $117,000
Q1 2022

May 20, 2022

SELL
$234.69 - $291.66 $11,734 - $14,583
-50 Reduced 12.5%
350 $100,000
Q1 2021

May 13, 2021

SELL
$164.32 - $212.72 $8,216 - $10,636
-50 Reduced 11.11%
400 $75,000
Q3 2020

Nov 12, 2020

SELL
$146.22 - $169.13 $102,354 - $118,391
-700 Reduced 60.87%
450 $67,000
Q4 2019

Feb 13, 2020

BUY
$106.92 - $132.43 $74,844 - $92,701
700 Added 155.56%
1,150 $151,000
Q3 2018

Nov 15, 2018

BUY
$85.86 - $107.31 $38,637 - $48,289
450 New
450 $48,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Resources Management Corp Portfolio

Follow Resources Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Resources Management Corp , based on Form 13F filings with the SEC.

News

Stay updated on Resources Management Corp with notifications on news.